Treatment of autoimmune disorders with CD154 antibodies

A method of treating systemic lupus erythematosus (SLE) comprising:

• a) administering an initial loading dose of about 30 mg/kg of a monovalent antibody fragment binding specifically to CD154, the antibody fragment comprising a light chain variable region (LCVR) having a CDR1, a CDR2 and a CDR3 comprising the amino acid sequence of SEQ ID NOs:1, 2 and 3, respectively, and a heavy chain variable region (HCVR) having a CDR1, a CDR2 and a CDR3 comprising the amino acid sequence of SEQ ID NOs:
• 4, 5 and 6, respectively, to a human subject having SLE;
• and
• b) about 2 weeks after the initial loading dose administering a further dose or doses of about 15 mg/kg of the monovalent antibody fragment binding specifically to CD154, with a frequency of about once every other week.